Q1 2025 Adaptive Biotechnologies Corp Earnings Call Transcript
Key Points
- Adaptive Biotechnologies Corp (ADPT) reported a 34% increase in MRD revenue year-over-year, demonstrating strong growth in clinical volumes, ASP, and pharma sequencing.
- The company achieved a significant improvement in sequencing gross margin, which increased by 17 percentage points to 62% year-over-year.
- Operating expenses decreased by 9%, highlighting disciplined cost management while maintaining growth.
- Adaptive Biotechnologies Corp (ADPT) raised its full-year guidance for MRD revenue, operating expenses, and cash burn, reflecting strong performance and sustained momentum.
- The company has a solid cash position of $233 million, providing ample runway to achieve strategic objectives without needing additional capital.
- Immune Medicine revenue decreased by 6% year-over-year, driven by a 23% decrease in Genentech amortization.
- Despite improvements, the MRD adjusted EBITDA remains at a loss of $4.1 million, although this is an improvement from the previous year.
- The Immune Medicine business continues to operate at a loss, with adjusted EBITDA showing a 21% improvement but still negative.
- The company faces challenges in achieving operational efficiencies from EMR integrations, with potential savings not yet factored into the 2025 guidance.
- There is uncertainty regarding the timing and magnitude of sequential growth in test volumes, as several strategic initiatives are still in early stages.
Good day and thank you for standing by. Welcome to the Adaptive Biotechnologies first-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Karina Calzadilla, Head of Investor Relations. Please go ahead.
Thank you, Antoine, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies first-quarter of 2025 earnings conference call.
Earlier today, we issued a press release reporting Adaptive financial results for the first quarter of 2025. The press release is available at www.adaptivebiotech.com. We are adopting a live webcast of this call and will be referencing a slide presentation that has been posted to the Investors Section in our corporate website.
During the call, management will make projections and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
